A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-26

Study Completion Date

2025-09-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This will be a first time in human (FTIH) study in sickle cell diseases (SCD) participants. The FTIH study is planned to evaluate the safety, tolerability, and pharmacokinetics of GSK4172239D.

The study will be composed of 3 periods for all participants (Screening, Treatment, and Follow up). Participants will be screened and, prior to first dose on Day 1, will be randomized to receive either GSK4172239D or placebo.

GSK4172239D is a prodrug that is converted in vivo into GSK4106401. This study will be a single dose, dose-escalation study. The initial dosing for all cohorts will be staggered so that 2 participants will be dosed as sentinel participants. Provided there are no safety concerns in 48 hours (h), the remaining 6 participants scheduled for the cohort may be dosed. One selected cohort of participants will also receive an additional single dose of GSK4172239D (or matching placebo) under fed (high calorie and high fat) conditions after a washout period of a minimum of 20 days or 5 half-lives, whichever is longer, designated as the Food Effect Cohort.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Sickle CEll Disease ComplicatioN Trial

NCT02604368

Sickle Cell Disease

UNKNOWN PHASE3

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT06546670

Sickle Cell Disease

RECRUITING PHASE1/PHASE2

Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

NCT04255875

Healthy Sickle Cell Anemia

COMPLETED PHASE1

Safety, Tolerability and Pharmacokinetics of FTX-6058

NCT04586985

Healthy Adult Subjects Sickle Cell Disease

COMPLETED PHASE1

A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)

NCT04983264

Sickle Cell Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematologic Diseases Anaemia, Sickle Cell

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This is a placebo controlled multi-center study.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

This study will be a double blinded study where the sponsor may be unblinded.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

Participants in this arm will receive either single dose of GSK4172239D (Dose 1) or matching placebo.

Group Type EXPERIMENTAL

GSK4172239D

Intervention Type DRUG

Different strength of GSK4172239D will be administered in different cohorts.

Placebo

Intervention Type OTHER

Matching placebo will be administered.

Cohort 2

Participants in this arm will receive either single dose of GSK4172239D (Dose 2) or matching placebo.

Group Type EXPERIMENTAL

GSK4172239D

Intervention Type DRUG

Different strength of GSK4172239D will be administered in different cohorts.

Placebo

Intervention Type OTHER

Matching placebo will be administered.

Cohort 3

Participants in this arm will receive either single dose of GSK4172239D (Dose 3) or matching placebo.

Group Type EXPERIMENTAL

GSK4172239D

Intervention Type DRUG

Different strength of GSK4172239D will be administered in different cohorts.

Placebo

Intervention Type OTHER

Matching placebo will be administered.

Cohort 4

Participants in this arm will receive either single dose of GSK4172239D (Dose 4) or matching placebo.

Group Type EXPERIMENTAL

GSK4172239D

Intervention Type DRUG

Different strength of GSK4172239D will be administered in different cohorts.

Placebo

Intervention Type OTHER

Matching placebo will be administered.

Cohort 5

Participants in this arm will receive either single dose of GSK4172239D (Dose 5) or matching placebo.

Group Type EXPERIMENTAL

GSK4172239D

Intervention Type DRUG

Different strength of GSK4172239D will be administered in different cohorts.

Placebo

Intervention Type OTHER

Matching placebo will be administered.

Food effect cohort

One selected cohort will also receive an additional single dose of GSK4172239D (or matching placebo) under fed (high calorie and high fat) conditions.

Group Type EXPERIMENTAL

GSK4172239D

Intervention Type DRUG

Different strength of GSK4172239D will be administered in different cohorts.

Placebo

Intervention Type OTHER

Matching placebo will be administered.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GSK4172239D

Different strength of GSK4172239D will be administered in different cohorts.

Intervention Type DRUG

Placebo

Matching placebo will be administered.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants diagnosed with SCD not taking medication which increases gamma-globin (fetal hemoglobin).
* Participants with SCD who have failed or not tolerated one or more approved therapies for SCD
* Body weight greater than (\>) 50 kilogram (kg).
* For male participants: Refrain from donating sperm plus either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. OR agree to use a male condom with female partner. Agree to use an additional highly effective contraceptive method with a failure rate of less than (\<) 1% per year when having sexual intercourse with a woman of childbearing potential who is not currently pregnant
* For female participants: Female participants are eligible to participate if they are a woman of non-childbearing potential (WONCBP).
* Capable of giving informed consent.

Exclusion Criteria

* Presence of active, clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drug; or interfering with the interpretation of data.
* Clinically significant abnormal blood pressure and/or history of hypertension as determined by the investigator.
* History of clinically significant heart disease as determined by the investigator.
* Estimated glomerular filtration rate (eGFR) \< 60 ml/min/1.73m\^2
* ALT \> 3x upper limit of normal (ULN).
* Bilirubin \> 5x ULN (isolated bilirubin \> 5x ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
* Hemoglobin \< 6 gram/decalitre (g/dL).
* Absolute neutrophil count \<1,500 / microlitre (μL).
* Platelet count \<75,000 /μL or \>750,000 /μL.
* Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 t1/2 (whichever is longer) prior to the first dose of study drug, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise participant safety. By exception, participant may take acetaminophen (less than or equal to \[≤\] 2 g/day) up to 48h prior to the first dose of study drug.
* Use of hydroxyurea or decitabine within 9 weeks prior to baseline through follow-up.
* Blood transfusion within 3 months prior to baseline through follow-up.
* Current enrollment or past participation within the last 30 days before signing of consent in this or any other clinical study involving an investigational study drug or any other type of medical research.
* Positive pre-study drug/alcohol screen. By exception, opioid use for pain or benzodiazepine use for anxiety as directed by a physician is permitted.
* Regular use of known drugs of abuse, except for use directed by a physician. By exception, opioid use for pain or benzodiazepine use for anxiety is permitted.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No